《Vaccine therapies for chronic hepatitis B： can we go further？.》.pdf

Front．Med．2014，8(1)：17—23 D0I10．1007／s11684—014—0313—7 REVIEW VaccinetherapieessftoorrcchrtoonnicchheeppaattiittiissB一：：ccaannweggoftuurrtthheere YumeiWen(函)。，XuanyiWang’。，BinWang，ZhenhongYuan KeyLaboratoryMedicalMolecularVirologyofMinistryofEducation~MinistryofHealth，ShanghaiMedicalCollege,FudanUniversity Shanghai200032，China,21nstitutesofBiomedicalSciences，ShanghaiMedicalCollege，FudanUniversiyt,Shanghai200032，China ◎ HigherEducationPressandSpringer-VerlagBerlinHeidelberg2014 Abstract ChronichepatitisBisamajorhealthburdenworldwide．Inadditiontotherecentprogressinantiviral treatment，therapeuticvaccinationisapromisingnew strategyforthecontrolofchronichepatitisB．Onthebasis ofthemajorspecificandnon-specificimmunedysregulationsanddefectsinchronichepatitisBpatients，thispaper presentsthepeptideandprotein-based，DNA-based，cell-based，andantigen-antib0dy-basedtherapeuticvaccines， whichhaveundergoneclinicaltrials．Theadvantages，disadvantages，andfutureperspectivesofrthesetherapeutic vaccinesarediscussed． Keywords chronichepatitisB：therapeutic；antigen—antibodycomplexes；DNA；vaccine lntroduction antiviraltherapy,responsesto immunotherapyvaryamong patientsbecausethetherapeutice币cacydependsonthestatus DespitethesignificantcontributionofpreventivehepatitisB ofinnate and adaptiveimmunity in patients．In vaccine vaccineinreducingtheincidenceofhepatitisBvirus(HBV) therapy,differentsubpopulationsofpatientsmay require carriersworldwide．approximately300millionpeoplearestill differenttherapeuticimm unization protocols．Giventhata infected with HBV Someofthese infectionsprogressto time lapse existsbetween immunization and immune chronic1iverdiseases．1ivercirrhosisandevenhepatocellular response development delayed efficacy in therapeutic carcinoma．AntiviraltreatmentforchronichepatitisB(CHB) va